potlimitomaha| Genetics technology company Youxun Medical submitted a statement to the Hong Kong Stock Exchange shareholders with luxurious background lineup

editor2024-05-01 02:20:2755

Youxun Medical Company submits A1 prospectus to HKExPotlimitomahaThe exclusive sponsor is China International Capital Corporation. The company is a platform-based genetic technology company engaged in the development and sale of clinical molecular testing instruments, products and services, including prenatal testing, precision oncology and pathogen detection. The company adopts the "LDT+IVD" two-track business model and has established a portfolio of 24 products and services that have been commercialized and 14 are under development.

The company supports the competitive advantage of products and services in the market through four core technologies: liquid biopsy, DNA methylation detection, NGS and POCT microfluidic biochip.

potlimitomaha| Genetics technology company Youxun Medical submitted a statement to the Hong Kong Stock Exchange shareholders with luxurious background lineup

The company has a comprehensive product portfolio, commercial LDT services across different fields, leading technology, and IVD candidate products have entered a later stage.

In terms of performance, Youxun Medicine recorded income from 2021 to 2023, respectively.Potlimitomaha65.7 billion yuan (RMB, the same below), 570.8 million yuan and 468.4 million yuan; gross profits were 199.6 million yuan, 217.9 million yuan and 303 million yuan respectively, and gross profit margins were 75.1%, 38.2% and 64.7%, respectively.

On average, four members of the company's management team have more than 15 years of experience in the medical industry, all from leading pharmaceutical and biological companies such as Huada Group and Merck, as well as top research institutions such as Peking University.

The company's shareholders include Huada Holdings, the industry leader of China's NGS sequencing platform, Decheng Capital, the government guidance fund ZGC Science City Ltd., and senior institutional investors in the field of genetic technology and innovation, such as Mainian Health, Infinity Capital, Jingfeng Qiyun and CITIC Guoan (000839), which have a national medical service network.